# Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes

**Authors:** Matthew Salmon, Nicole Naumann, Jenny Rinke, Manja Meggendorfer, Deepti Radia, Mark Pomfret, Thomas Ernst, Andreas Hochhaus, Andreas Reiter, William J. Tapper, Helen White, Nicholas C. P. Cross

PMC · DOI: 10.1038/s41375-025-02801-5 · Leukemia · 2025-11-18

## TL;DR

This paper shows how nanopore DNA sequencing can quickly and accurately detect tyrosine kinase fusion genes in blood cancers.

## Contribution

The study introduces adaptive sampling with nanopore sequencing for precise detection of diverse tyrosine kinase fusion genes.

## Key findings

- Nanopore sequencing identified 18 TK fusions in 20 patient samples, including known and novel fusion events.
- The method detected complex rearrangements like deletions and multiple translocations with high accuracy.
- The approach is fast, flexible, and requires minimal hands-on time for genomic breakpoint characterization.

## Abstract

Diverse haematological neoplasms are driven by tyrosine kinase (TK) fusion genes formed by recurrent or non-recurrent genomic rearrangements. The resulting chimeric proteins often present excellent targets for treatment with kinase inhibitors, and the fusion transcripts or genomic junctions can be used as specific targets for molecular monitoring. Whilst the TK genes involved are generally well characterised (e.g. ABL1, PDGFRA, FGFR1), the fusion partners are very diverse, presenting a challenge for detection and characterisation of these structural variants (SV) using current diagnostic methods. We assessed the ability of targeted nanopore sequencing using adaptive sampling to detect fusion genes in myeloid neoplasms. We sequenced genomic DNA from patients (n = 20) with a known or suspected TK gene fusion and identified rearrangements in 18 cases, including all cases with a known TK fusion, typical and atypical BCR::ABL1 rearrangements, an 843Kb deletion causing a FIP1L1::PDGFRA fusion, novel AGAP2::PDGFRB and NFIA::PDGFRB fusions, and a complex CCDC88C::PDGFRB rearrangement with multiple translocation events. The approach was fast (<72 h/sample from DNA to result), flexible with minimal hands-on laboratory time, and provided accurate, patient-specific characterisation of genomic breakpoints.

## Linked entities

- **Genes:** ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156], FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260], BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613], ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25], FIP1L1 (factor interacting with PAPOLA and CPSF1) [NCBI Gene 81608], PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156], AGAP2 (ArfGAP with GTPase domain, ankyrin repeat and PH domain 2) [NCBI Gene 116986], PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159], NFIA (nuclear factor I A) [NCBI Gene 4774], PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159], CCDC88C (coiled-coil and HOOK domain protein 88C) [NCBI Gene 440193], PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159]

## Full-text entities

- **Genes:** ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, PDGFRA (platelet derived growth factor receptor alpha) [NCBI Gene 5156] {aka CD140A, PDGFR-2, PDGFR2}, TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}
- **Diseases:** haematological neoplasms (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12789007/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12789007/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12789007/full.md

---
Source: https://tomesphere.com/paper/PMC12789007